Rabe KF, Vermeire PA, Soriano JB, Maier WC Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J, 2000. 16: 802-807.
Partridge MR van der Molen T, Myrseth SE, Busse WW. BMCPulm Med, 2006. 6: 13.
Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. Primary Care Respir Med 2014; article number 14009.
Емельянов А.В., Горячкина Л.А., Астафьева Н.Г. и соавт. Аллергический ринит и бронхиальная астма в реальной клинической практике: результаты Российского многоцентрового исследования. Российский аллергологический журнал, 2012. 1: 29-33.
Global Initiative for Asthma. NHLB/WHO Workshop Report-National Heart Lung Blood Institute, Publication number 02-3659, revised 2015. Available at: http www.ginasthma.org.
Чучалин А.Г, Айсанов З.Р., Белевский А.С. и др. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. Под ред. А.Г". Чучалина. М., 2013, 18 с.
Sharpe M, Jarvis B. Inhaled mometasone furoate. A review of its use in adults and adolescents with persistent asthma. Drugs, 2001. 61: 1325-1350.
Chapman RW, Sehring SL, Gallisi CG et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittel Forshung, 1998. 48: 384-391.
Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs, 1998. 55(2): 303-322.
Nolte H, Pavord I, Backer V et al. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respir Med, 2013. 107: 656-664.
Frampton JE. Mometasone/Formoterol Inhalation Aerosol In Asthma Uncontrolled on Medium- or High-Dose Inhaled Corticosteroids. Drugs, 2012. 72(9): 1229-1241.
Berger WE. Mometasone furoate/formoterol in the treatment of persistent asthma. Expert Rev. Respir Med., 2011. 5(6): 739-746.
Affrime MB, Cuss F, Padhi D et al. Bioavailability and metabolism of mometasone furoate following administration by metered- dose and dry- powder inhalers in healthy volunteers. J Clin Pharm., 2000. 40: 1227-1236.
Affrime MB, Kosoglou T. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild and moderate persistent asthma. J Allergy Clin Immunol., 2001. 107, 104.
Padden J, Skoner D and Hochhaus G. Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids. Journal of Asthma, 2008. 45(Suppl. 1): 13-24.
Meltzer EO, Kuna P, Nolte H et al. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J., 2012. 39(2): 279-289.
Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 mg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled cortico-steroids. Allergy Asthma Proc, 2010. 31(4): 269-79.
Weinstein SF, Corren J, Murphy K, et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 mg and 400/10 mg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticos-teroids. Allergy Asthma Proc, 2010. 31 (4): 280-9.
Bernstein D, Hebert J, Cheema A et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/ salmeterol combination treatment in subjects with persistent asthma. Allergy, Asthma & Clinical Immunology, 2011. 7: 21.
Maspero JF, Nolte H, Cherrez-Ojeda I et al. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J Asthma, 2010; 47: 1106-15.
Westergaard C, Porsbjerg C, Backer V. A review of mometasone furoate. Formoterol in the treatment of asthma. Expert Opinion on Pharmacotherapy, 2013. 14(3): 339-346.
Зенхейл. Инструкция по медицинскому применению, 2012.
Weinstein C, Staudinger H, Scott I et al. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir Med., 2011. 105: 979-988.